Author(s):
Christopher N Floyd
Added:
3 years ago
Antiplatelet therapy represents a key pharmacological pillar for the prevention of atherothrombotic events. Aspirin, the primogenial antiplatelet agent, has been shown to reduce the incidence of recurrent major adverse cardiovascular events (MACE) by approximately one-fifth.1 Dual antiplatelet therapy (DAPT), usually aspirin in combination with a P2Y12 inhibitor, provides greater platelet…
View more
Author(s):
Tamara García Camarero,
José M de la Torre Hernández
Added:
3 years ago
The use of dual antiplatelet therapy (DAPT) after stent implantation in a percutaneous coronary intervention (PCI) is the standard treatment. The first randomised controlled trial (RCT) to establish the superiority of DAPT versus oral anticoagulant treatment among patients undergoing PCI was the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial, published in 1996.1 Since then, more…
View more
Author(s):
Giulio G Stefanini
Added:
2 years ago
Dr Giulio Stefanini (Humanitas Research Hospital, Milan, IT) discusses the findings from the multicentre POEM trial.The trial assessed the safety of the bioresorbable polymer-coated everolimus-eluting Synergy® stent in CAD patients undergoing PCI, followed by 1-month dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR).
Questions:
1. What is the POEM Study and what does it…
View more
Author(s):
Olaf Schouten,
Don Poldermans
Added:
3 years ago
Percutaneous coronary angioplasty with stenting is commonly used for treatment of symptomatic coronary artery disease (CAD). The introduction of stents has reduced the incidence of restenosis, one of the major drawbacks of coronary angioplasty, and proved to be an alternative treatment for bypass surgery. Recently, drug-eluting stents were introduced as a means to lower restenosis rates even…
View more